{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:36:55Z","timestamp":1790739415892,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier","isbn-type":[{"value":"9780128177402","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672585"],"award-info":[{"award-number":["81672585"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmbts.2019.02.004","type":"book-chapter","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T09:14:35Z","timestamp":1553159675000},"page":"41-53","source":"Crossref","is-referenced-by-count":55,"title":["The clinical use of Fondaparinux: A synthetic heparin pentasaccharide"],"prefix":"10.1016","member":"78","reference":[{"issue":"18","key":"10.1016\/bs.pmbts.2019.02.004_bb0010","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1016\/S0021-9258(19)43472-8","article-title":"The purification and mechanism of action of human antithrombin-heparin cofactor","volume":"248","author":"Rosenberg","year":"1973","journal-title":"J Biol Chem."},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.004_bb0015","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJM197501162920307","article-title":"Actions and interactions of antithrombin and heparin","volume":"292","author":"Rosenberg","year":"1975","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.004_bb0020","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0006-291X(79)90260-2","article-title":"Highly active heparin species with multiple binding sites for antithrombin","volume":"86","author":"Rosenberg","year":"1979","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.004_bb0025","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1073\/pnas.81.4.1030","article-title":"Evaluation of critical groups required for the binding of heparin to antithrombin","volume":"81","author":"Atha","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.02.004_bb0030","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1073\/pnas.77.11.6551","article-title":"Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin","volume":"77","author":"Lindahl","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/bs.pmbts.2019.02.004_bb0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0065-2318(01)57017-1","article-title":"Structure and biological interactions of heparin and heparan sulfate","volume":"57","author":"Casu","year":"2001","journal-title":"Adv Carbohydr Chem Biochem"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.004_bb0040","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/0006-291X(83)90550-8","article-title":"Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity","volume":"116","author":"Choay","year":"1983","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.004_bb0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0008-6215(00)90633-5","volume":"147","author":"Petitou","year":"1986","journal-title":"Carbohydr Res"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.004_bb0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0006-291X(85)91655-9","article-title":"Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue","volume":"128","author":"Torri","year":"1985","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.004_bb0055","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0008-6215(94)00334-C","article-title":"Dynamics in aqueous solutions of the pentasaccharide corresponding to the binding site of heparin for antithrombin III studied by NMR relaxation measurements","volume":"268","author":"Hricovini","year":"1995","journal-title":"Carbohydr Res"},{"issue":"18","key":"10.1016\/bs.pmbts.2019.02.004_bb0060","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/bs.pmbts.2019.02.004_bb0065","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM200103013440901","article-title":"A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement","volume":"344","author":"Turpie","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.004_bb0070","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/00062752-200209000-00006","article-title":"Heparin pentasaccharide","volume":"9","author":"Gallus","year":"2002","journal-title":"Curr Opin Hematol"},{"issue":"16","key":"10.1016\/bs.pmbts.2019.02.004_bb0075","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.004_bb0080","first-page":"137","article-title":"Development of a synthetic heparin pentasaccharide: fondaparinux","volume":"19","author":"Walenga","year":"2002","journal-title":"Turkish J Haematol Off J Turkish Soc Haematol"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.004_bb0085","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1517\/13543784.11.3.397","article-title":"Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent","volume":"11","author":"Walenga","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"issue":"suppl 2","key":"10.1016\/bs.pmbts.2019.02.004_bb0090","first-page":"143","article-title":"A new synthetic pentasaccharide with increased anti-factor Xa activity: possible role for anionic clusters in the interaction of heparin and antithrombin III","volume":"17","author":"Petitou","year":"1991","journal-title":"Semin Thromb Hemost"},{"issue":"18","key":"10.1016\/bs.pmbts.2019.02.004_bb0095","doi-asserted-by":"crossref","first-page":"15971","DOI":"10.1074\/jbc.M108131200","article-title":"Molecular determinants of the mechanism underlying acceleration of the interaction between antithrombin and factor Xa by heparin pentasaccharide","volume":"277","author":"Quinsey","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmbts.2019.02.004_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1877-1173(10)93001-9","article-title":"Glycosaminoglycan (GAG) biosynthesis and GAG-binding proteins","volume":"93","author":"Zhang","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"45","key":"10.1016\/bs.pmbts.2019.02.004_bb0105","doi-asserted-by":"crossref","first-page":"42311","DOI":"10.1074\/jbc.M101441200","article-title":"6-O-sulfotransferase-1 represents a critical enzyme in the anticoagulant heparan sulfate biosynthetic pathway","volume":"276","author":"Zhang","year":"2001","journal-title":"J Biol Chem"},{"issue":"31","key":"10.1016\/bs.pmbts.2019.02.004_bb0110","doi-asserted-by":"crossref","first-page":"28806","DOI":"10.1074\/jbc.M100204200","article-title":"The effect of precursor structures on the action of glucosaminyl 3-O-sulfotransferase-1 and the biosynthesis of anticoagulant heparan sulfate","volume":"276","author":"Zhang","year":"2001","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/bs.pmbts.2019.02.004_bb0115","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1074\/jbc.274.9.5681","article-title":"Anticoagulant heparan sulfate precursor structures in F9 embryonal carcinoma cells","volume":"274","author":"Zhang","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmbts.2019.02.004_bb0120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1877-1173(10)93008-1","article-title":"Anticoagulant heparan sulfate to not clot\u2014or not?","volume":"93","author":"Shworak","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"18","key":"10.1016\/bs.pmbts.2019.02.004_bb0125","doi-asserted-by":"crossref","first-page":"12528","DOI":"10.1016\/S0021-9258(18)42309-5","article-title":"Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement","volume":"267","author":"Olson","year":"1992","journal-title":"J Biol Chem"},{"issue":"48","key":"10.1016\/bs.pmbts.2019.02.004_bb0130","doi-asserted-by":"crossref","first-page":"50267","DOI":"10.1074\/jbc.M408774200","article-title":"The heparin binding properties of heparin cofactor II suggest an antithrombin-like activation mechanism","volume":"279","author":"O'Keeffe","year":"2004","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.004_bb0135","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MBC.0b013e328343f859","article-title":"Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels","volume":"22","author":"Jeske","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"suppl 2","key":"10.1016\/bs.pmbts.2019.02.004_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-200241002-00001","article-title":"The pharmacokinetics of fondaparinux sodium in healthy volunteers","volume":"41","author":"Donat","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.004_bb0145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-2007-1004364","article-title":"Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharide","volume":"11","author":"Walenga","year":"1985","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.004_bb0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00001721-199704000-00002","article-title":"Pharmacokinetic study of three synthetic AT-binding pentasaccharides in various animal species-extrapolation to humans","volume":"8","author":"Herault","year":"1997","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.004_bb0155","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.thromres.2013.04.016","article-title":"Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin","volume":"131","author":"Fukuda","year":"2013","journal-title":"Thromb Res"},{"issue":"15","key":"10.1016\/bs.pmbts.2019.02.004_bb0160","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood-2014-03-559518","article-title":"Binding of anti-platelet factor 4\/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4","volume":"124","author":"Kreimann","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.02.004_bb0165","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/1076029616646873","article-title":"Efficacy and safety of Fondaparinux in patients with suspected heparin-induced thrombocytopenia","volume":"22","author":"Snodgrass","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.004_bb0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2014.03.029","article-title":"Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)\u2014findings from the GerHIT multi-centre registry study","volume":"134","author":"Schindewolf","year":"2014","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.004_bb0175","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/j.jvca.2013.09.008","article-title":"Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients","volume":"28","author":"Cegarra-Sanmartin","year":"2014","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.004_bb0180","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/aor.12002","article-title":"Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: dose-finding study and safety evaluation","volume":"37","author":"Mahieu","year":"2013","journal-title":"Artif Organs"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.004_bb0185","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1160\/TH07-04-0252","article-title":"Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia","volume":"99","author":"Lobo","year":"2008","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.004_bb0190","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/ijccm.IJCCM_189_17","article-title":"The Fondaparinux paradox: fondaparinux-related heparin-induced thrombocytopenia","volume":"22","author":"Vadi","year":"2018","journal-title":"Indian J Crit Care Med"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.004_bb0195","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.12179","article-title":"Fondaparinux-associated heparin-induced thrombocytopenia","volume":"91","author":"Bhatt","year":"2013","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.004_bb0200","first-page":"13","article-title":"Fondaparinux-associated heparin-induced thrombocytopenia","volume":"25","author":"Burch","year":"2012","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"25","key":"10.1016\/bs.pmbts.2019.02.004_bb0205","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1056\/NEJMc070346","article-title":"Heparin-induced thrombocytopenia associated with fondaparinux","volume":"356","author":"Warkentin","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.004_bb0210","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0897190010362170","article-title":"Fondaparinux (Arixtra(R)), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia?","volume":"23","author":"Badger","year":"2010","journal-title":"J Pharm Pract"},{"issue":"18","key":"10.1016\/bs.pmbts.2019.02.004_bb0215","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/bs.pmbts.2019.02.004_bb0220","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2019.02.004_bb0225","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cca.2015.01.004","article-title":"Anti-Xa activity in VTE patients treated with fondaparinux","volume":"442","author":"Ota","year":"2015","journal-title":"Clin Chim Acta Int J Clin Chem"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.004_bb0230","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/jcpt.12315","article-title":"Fondaparinux vs. enoxaparin in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) treated with percutaneous coronary intervention and tirofiban: an exploratory study in China","volume":"40","author":"Zhao","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/bs.pmbts.2019.02.004_bb0235","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.thromres.2018.04.001","article-title":"Fondaparinux versus nadroparin for thromboprophylaxis following minimally invasive esophagectomy: a randomized controlled trial","volume":"166","author":"Song","year":"2018","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.004_bb0240","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1055\/s-0038-1645206","article-title":"Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats","volume":"63","author":"Hobbelen","year":"1990","journal-title":"Thromb Haemost"},{"issue":"111","key":"10.1016\/bs.pmbts.2019.02.004_bb0245","first-page":"266A","article-title":"Effect on efficacy and safety of the timing of the first pentasaccharide (fondaparinux, Arixtra (R)) administration in the prevention of venous thromboembolism (VTE) after major orthopedic surgery","volume":"98","author":"Turpie","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.004_bb0250","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1160\/TH03-07-0483","article-title":"Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood","volume":"91","author":"Gerotziafas","year":"2004","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.004_bb0255","first-page":"184","article-title":"Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid","volume":"63","author":"Huvers","year":"2005","journal-title":"Neth J Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.004_bb0260","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/107602960100700112","article-title":"Synthetic heparin pentasaccharide depolymerization by heparinase I: molecular and biological implications","volume":"7","author":"Daud","year":"2001","journal-title":"Clin Appl Thromb Hemost"},{"issue":"111","key":"10.1016\/bs.pmbts.2019.02.004_bb0265","first-page":"52A","article-title":"Heparinase is capable of neutralizing the anticoagulant and hemorrhagic effects of a synthetic pentasaccharide","volume":"96","author":"Iqbal","year":"2000","journal-title":"Blood"},{"issue":"19","key":"10.1016\/bs.pmbts.2019.02.004_bb0270","doi-asserted-by":"crossref","first-page":"10365","DOI":"10.1073\/pnas.97.19.10365","article-title":"Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin","volume":"97","author":"Shriver","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.02.004_bb0275","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4103\/ijccm.IJCCM_205_17","article-title":"Prophylaxis and incidence of symptomatic deep vein thrombosis in Indian patients with sepsis: detect-deep vein thrombosis registry","volume":"21","author":"Ramakrishnan","year":"2017","journal-title":"Indian J Crit Care Med"},{"key":"10.1016\/bs.pmbts.2019.02.004_bb0280","unstructured":"McLendon K, Attia M. Deep Venous Thrombosis (DVT), Risk Factors, StatPearls Publishing, 2018-01-012018."},{"issue":"111","key":"10.1016\/bs.pmbts.2019.02.004_bb0285","doi-asserted-by":"crossref","first-page":"6A","DOI":"10.1182\/blood.V108.11.6.6","article-title":"Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep-vein thrombosis or pulmonary embolism\u2014the van Gogh investigators","volume":"108","author":"Buller","year":"2006","journal-title":"Blood"},{"issue":"111","key":"10.1016\/bs.pmbts.2019.02.004_bb0290","article-title":"Once weekly subcutaneous idraparinux versus placebo in the extended treatment of deep-vein thrombosis or pulmonary embolism. The van Gogh investigators","volume":"108","author":"Buller","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.pmbts.2019.02.004_bb0295","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2147\/TCRM.S153517","article-title":"The clinical course of symptomatic deep vein thrombosis after 3 months of anticoagulant therapy using fondaparinux\/edoxaban or fondaparinux\/vitamin K antagonist","volume":"14","author":"Shimizu","year":"2018","journal-title":"Ther Clin Risk Manag"},{"issue":"13","key":"10.1016\/bs.pmbts.2019.02.004_bb0300","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"}],"container-title":["Progress in Molecular Biology and Translational Science","Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117319300250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117319300250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T03:59:37Z","timestamp":1761796777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117319300250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128177402"],"references-count":59,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2019.02.004","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}